Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver

 Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver

NEW OBSERVATIONAL DATA: In people with type 2 diabetes (T2D) and compensated liver cirrhosis, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use reduces the risk for death, cardiovascular disease, decompensated cirrhosis, and liver failure.

                            METHODOLOGY: Data from Taiwan's National Health Insurance Research Database were used in this population-based cohort study.

467 matched pairs of GLP-1 RA users and nonusers with T2D and compensated liver cirrhosis (mean age, 57) were created using propensity-score matching.

In multivariable-adjusted Cox proportional hazards models, all-cause mortality, cardiovascular events, decompensated cirrhosis, and other important outcomes were compared.

TAKEAWAY: Death rates per 1000 person-years during a mean follow-up of around 3 years were 27.5 in GLP-1 RA users compared

Comments

Popular posts from this blog

Griselda: Where Fact Blends with Fiction in the Cocaine Godmother's Story

BEST MOBILE PHONE 2023